Thomas Civik - 03 Feb 2026 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Interim CEO, Director
Signature
/s/ Jitu Wadhane, Attorney-in-Fact for Thomas Civik
Issuer symbol
PYXS
Transactions as of
03 Feb 2026
Net transactions value
$0
Form type
4
Filing time
05 Feb 2026, 20:37:38 UTC
Previous filing
28 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Civik Thomas Interim CEO, Director C/O PYXIS ONCOLOGY, INC., 321 HARRISON AVENUE, 11TH FL. SUITE 1, BOSTON /s/ Jitu Wadhane, Attorney-in-Fact for Thomas Civik 05 Feb 2026 0001723092

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to Buy) Award $0 +690,131 $0.000000 690,131 03 Feb 2026 Common Stock 690,131 $1.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest in 12 equal monthly installments, commencing on the grant date and subject to the reporting person's continued service as Interim Chief Executive Officer through the applicable vesting date.